Cell and gene therapies in the US vs. the EU: Top 5 areas of differentiation
For cell and gene therapies (CGTs) and other complex biologics, US and EU regulatory processes vary by more than just jurisdictional oversight.
In this eBook, we share:
- Guidance for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval
- Five key differences in the drug development and review process
- Top tips for navigating these differences
Download this eBook to maximize your chance at market approval in both jurisdictions.
© 2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. We hereby disclose that this email communication is for commercial purposes.
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper